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Dear Editor
Ethyl glucuronide (EtG) is a promising biomarker for assessing alcohol use in clinical 
settings, as it can detect alcohol use up to five days prior in urine, depending on the amount 
of alcohol consumed and individual factors, using a spectrophotometry-based 
immunoassay1–3 (DRI; Diagnostics Reagents Incorporated, Sunnyvale, CA). Our work has 
demonstrated that this DRI EtG immunoassay has high agreement with EtG mass 
spectrometry (the “gold standard” EtG LC-MS/MS test), with agreement varying based on 
the cutoff level used (91% for EtG 100 ng/mL, 96% for EtG 300 ng/mL)1,2,4–6. While no 
consensus exists about the utility of cutoff levels under 500 ng/mL, our work and the work 
of others suggest that cutoffs of 100–300 ng/mL are best for detecting drinking up to five 
days prior, depending on the amount of alcohol consumed1,7. These cutoffs are not 
associated with inadvertent alcohol exposure1,3,8.
While EtG immunoassays could serve as an accurate means of detecting alcohol use in 
research and clinical settings, the DRI immunoassay in question requires a $30,000 analyzer, 
as well as testing reagents and trained staff3,8,9. These constraints have limited the ability of 
clinical researchers and providers to use the EtG immunoassay to test for alcohol use. 
However, point-of-care EtG immunoassay dipcards with cutoff levels that are likely to detect 
recent drinking (i.e., EtG 300 ng/mL) have recently become available at a low cost ($5). 
Such point-of-care urine tests are available and commonly used for drugs in clinical settings, 
as they provide low-cost, accurate and immediate results10–12. Thus, if shown to be similarly 
accurate, these point-of-care EtG-dipcard tests could increase the feasibility of EtG testing in 
research and clinical settings. However, no independent data have verified the accuracy of 
point-of-care EtG-dipcard tests. In this letter, we report levels of agreement between two 
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EtG immunoassay tests: spectrophotometry-based DRI EtG tests conducted on an Indiko 
benchtop analyzer (EtG-benchtop) and point-of-care EtG-dipcard tests.
In this small pilot study a total of 53 urine samples were gathered from 5 non-alcohol 
treatment seeking adults who self-reported recent heavy drinking, defined by >4 standard 
drinks in one sitting on >4 out of the last 30 days. Urine samples were tested for the 
presence of EtG using the Diagnostic Reagents Incorporated enzyme immunoassay and a 
point-of-care dipcard (Confirm Biosciences, San Diego, CA) at a cutoff of 300 ng/mL.
Participants met DSM-V criteria for a mild (n=4) or moderate (n=1) alcohol use disorder13. 
They were 60% female with a mean age of 45.6 (SD=17.3), and self-reported Caucasian 
(60%, n=3); Black, (20%, n=1) or more than one race (Caucasian and American Indian, 
20%, n=1). Most had completed at least two years of college (14 years of education; M=15; 
SD=1.73). Participants had a mean body mass index score in the overweight range (M=27.4; 
SD=2.38). Using the Alcohol Timeline Followback14, participants self-reported a mean of 
13.8 (SD=8.23) days of alcohol use in the 30 days prior to baseline. Participants also 
reported a mean of 10.6 (SD=5.68) heavy drinking days in the 30 days prior to baseline. 
Participants provided written informed consent for study procedures, which were approved 
by the Washington State University Institutional Review Board.
A total of 53 urine samples were collected and analyzed at baseline and weekly for 10 
weeks. EtG-dipcard analysis was conducted after completion of the study visit in a manner 
consistent with the product insert: The sample was held at room temperature for 5–10 
minutes before the EtG-dipcard was inserted. The EtG-dipcard cap was removed and the tip 
of the dipcard was immersed into the sample for 15 seconds. The EtG-dipcard was re-
capped and results were read after 5 minutes. Results of the EtG-dipcard test were 
interpreted by reading the panel on the card, wherein the appearance of two lines indicated a 
negative result and one line indicated a positive result. While our previous work has 
indicated that lower EtG cutoff levels (i.e. 100 ng/mL, 200 ng/mL) are ideal for clinical 
settings, we used a dipcard with the 300 ng/mL cutoff level, as this was the lowest cutoff 
currently available.
EtG-benchtop immunoassay tests were conducted using spectrophotometry on a 
ThermoFisher Indiko benchtop analyzer (Fremont, CA). Analyses were conducted using 
EtG 100 ng/mL, 500 ng/mL, 1000 ng/mL, 2000 ng/mL, and Negative calibrators and EtG 
100 ng/mL and 375 ng/mL controls. Acceptance criteria for controls were within 25% of the 
control value. Antibody/Substrate and Enzyme Conjugate reagents were used and the 
analyzer was calibrated weekly. Samples were stored at 4°C until they were mailed 
overnight to the analysis site in a refrigerated package and analyzed between 2 to 5 days 
after the day of collection. During analysis, a rack of samples including eight drops of urine, 
eight drops of 100 ng/mL control, and eight drops of 375 ng/mL control was inserted into 
the machine. A separate rack containing the reagents was inserted. When analysis was 
complete, results were reported on an attached desktop computer. The reportable range of 
the immunoassay was 100 ng/mL to 2000 ng/mL. Dilution procedures were conducted when 
EtG-benchtop results displayed an error message indicating the test result was outside of the 
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calibration range. Nineteen samples (39%) required dilution, and were re-run with four 
drops urine and four drops of negative calibrator added as the diluent.
Ninety-eight percent agreement was observed with 52 of the 53 urine samples submitted 
(98% agreement, kappa=.96). For a single sample, the EtG-dipcard was positive and EtG-
benchtop was negative, with a value of <100 ng/mL. Sensitivity was 100% and specificity 
was 97%. EtG-Indiko results had a median of 100 ng/mL (IQR=100–691.6 ng/mL). Figure 1 
displays the raw values of all EtG-Indiko results. Importantly, 9 samples (17%) had an EtG-
Indiko result that was ± 200 ng/mL of the 300 ng/mL dipcard cutoff.
This high rate of agreement between the point-of-care EtG-dipcard and a 
spectrophotometry-based EtG-benchtop immunoassay provides initial support for the 
accuracy of EtG-dipcard tests. While this is a pilot study with a small number of samples, it 
provides promising preliminary data with which to base a larger study on the accuracy of the 
EtG-dipcard. A future study could use dilution to systematically evaluate EtG-Indiko results 
near the EtG-dipcard cutoff of 300 ng/mL. Additionally, future studies are needed 
comparing the EtG-dipcard to EtG-LC-MS/MS, rather than to another immunoassay. 
Development of an EtG-dipcard with lower cutoff levels (e.g. 100–200 ng/mL) is also 
recommended to better detect alcohol use in non-forensic settings. As such, even at the 300 
ng/mL cutoff level EtG-dipcard tests have great potential to improve the utility of EtG as a 
tool for monitoring alcohol use in both clinical and research settings. EtG-dipcards are less 
expensive (approximately $5 per card) and more feasible than EtG-benchtop immunoassays, 
making them ideal for screening and assessment of alcohol use in treatment settings, as well 
as intervention approaches, such as contingency management, which require low-cost and 
immediate verification of alcohol abstinence.
Sincerely,
Emily Leickly, B.A.
Jordan Skalisky, B.A.
Sterling McPherson, Ph.D.
Michael F. Orr B.A., B.S.
Michael G. McDonell, Ph.D.
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Figure 1. 
Plot of 53 ethyl glucuronide immunoassay test results conducted on the Indiko benchtop 
analyzer (EtG-benchtop). X indicates agreement between EtG-benchtop and EtG-dipcard. O 
indicates non-agreement. One disagreement occurred when the EtG-dipcard was positive but 
the EtG-benchtop result was < 100 ng/mL. EtG values under 100 ng/mL were plotted at 100 
ng/mL.
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